These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 29470579)

  • 1. Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.
    Ritchie G; Gasper H; Man J; Lord S; Marschner I; Friedlander M; Lee CK
    JAMA Oncol; 2018 Apr; 4(4):522-528. PubMed ID: 29470579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
    Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
    JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang ZX; Wu HX; Xie L; Wang YN; Yang LP; He MM; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
    JAMA Netw Open; 2019 May; 2(5):e193433. PubMed ID: 31050784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
    Blumenthal GM; Zhang L; Zhang H; Kazandjian D; Khozin S; Tang S; Goldberg K; Sridhara R; Keegan P; Pazdur R
    JAMA Oncol; 2017 Aug; 3(8):e171029. PubMed ID: 28617920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
    Kaufman HL; Schwartz LH; William WN; Sznol M; Fahrbach K; Xu Y; Masson E; Vergara-Silva A
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2245-2261. PubMed ID: 30132118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
    Mushti SL; Mulkey F; Sridhara R
    Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
    Lee CK; Man J; Lord S; Cooper W; Links M; Gebski V; Herbst RS; Gralla RJ; Mok T; Yang JC
    JAMA Oncol; 2018 Feb; 4(2):210-216. PubMed ID: 29270615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies.
    Roviello G; Andre F; Venturini S; Pistilli B; Curigliano G; Cristofanilli M; Rosellini P; Generali D
    Eur J Cancer; 2017 Nov; 86():257-265. PubMed ID: 29055841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis.
    Kok PS; Yoon WH; Lord S; Marschner I; Friedlander M; Lee CK
    JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34296055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials.
    Hu C; Wang M; Wu C; Zhou H; Chen C; Diede S
    JAMA Netw Open; 2021 May; 4(5):e218175. PubMed ID: 34047794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
    Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
    Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
    Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
    Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
    Gyawali B; Hey SP; Kesselheim AS
    JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
    Nie RC; Chen FP; Yuan SQ; Luo YS; Chen S; Chen YM; Chen XJ; Chen YB; Li YF; Zhou ZW
    Eur J Cancer; 2019 Jan; 106():1-11. PubMed ID: 30453169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
    Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W
    Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials.
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ; Kim KW
    Korean J Radiol; 2020 Apr; 21(4):471-482. PubMed ID: 32193895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
    Hua T; Gao Y; Zhang R; Wei Y; Chen F
    BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
    Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
    JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.